MAIA Biotechnology, Inc. MAIA 深 沪
已收盘 10-02 16:00:00 美东时间
1.19
+0.020
+1.71%
华盛通- 最 高1.21
- 今 开1.19
- 成交量 40.50万股
- 最 低 1.17
- 昨 收 1.17
- 总市值 7347.29万
- 52周最高 3.19
- 市盈率 静 --
- 换手率 0.66%
- 52周最低 0.87
- 委 比 -18.43%
- 总股本 6174.19万
- 历史最高 9.64
- 量 比 0.50
- 振 幅 3.42%
- 历史最低 0.82
- 每 手 1
- 风险率 0.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MAIA Biotechnology Receives Regulatory Approval By The Spanish Agency For Medicines And Medical Devices And Portugal’s National Authority Of Medicines And Health Products To Begin Screening Patients For Its Ongoing Pivotal Phase 3 THIO-104 Clinical Trial In Non-Small Cell Lung Cancer
THIO-104 advances toward key 2027 interim survival analysis CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that it has received regu...
09-23 21:18
MAIA Biotechnology Says First US Patient Dosed In Phase 2 THIO-101 Trial Expansion Evaluating Telomere-Targeting Lead Candidate, Ateganosine, In Third-Line Non-Small Cell Lung Cancer
Milestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies U.S. expansion is funded by a $2.3 million NIH grant to MAIA to support third-line treatment evaluation CHICAGO, Sept. 16, 2026 (GLOBE NEWSWI...
09-16 20:16
MAIA Biotechnology Reports 90.5% Disease Control Rate In Phase 2 THIO-101 Clinical Trial Of Ateganosine For Advanced Non-Small Cell Lung Cancer
90.5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated patient population CHICAGO, July 08, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MA...
07-08 21:53
MAIA Biotechnology Completes Global Enrollment In Part C Of Its Phase 2 THIO-101 Expansion Study Of Ateganosine To Treat Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has completed international enrollment in Part C of its Phase 2 THIO-101 expansion trial evaluating its lead can...
06-25 20:10
MAIA Biotechnology Insiders Founder/CEO Vlad Vitoc, M.D. And Director Stan V. Smith, Ph.D. Increase Ownership Position Through Open Market Purchases Of ~147,700 Shares Worth ~$201K
Approximately 72,700 shares of MAIA common stock were purchased by Dr. Vitoc on June 6, 2026, at an average common stock price of $1.3877. Approximately 75,000 shares of MAIA common stock were purchased by Dr. Smith on
06-02 21:54
MAIA Biotechnology Q1 EPS $(0.14) Beats $(0.18) Estimate
MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.18) by 22.22 percent. This is a 12.5 percent increase over losses of $(0.16) per share from
05-11 21:31
MAIA Biotechnology Activates First Clinical Facility In U.S. In Its Phase 2 THIO-101 Expansion Study To Treat Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has activated the first U.S.
04-16 21:23
MAIA Biotechnology Reports Over 2-Year Survival In Phase 2 THIO-101 NSCLC Trial;
Potential breakthrough therapeutic targets $50B+ global immunotherapy market1CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical
03-31 21:19
MAIA Biotechnology Q4 EPS $(0.08) Beats $(0.13) Estimate
MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.13) by 38.46 percent. This is a 33.33 percent increase over losses of $(0.12) per share from
03-24 06:11
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Edesa Biotech (NASDAQ:EDSA) shares rose 61.0% to $3.67 during Tuesday'...
03-04 01:05
